<DOC>
	<DOCNO>NCT01010425</DOCNO>
	<brief_summary>Double-blind , randomize , placebo active control dose-ascending study investigate safety , tolerability , pharmacokinetics pharmacodynamics ACP-001 ( TransCon PEG hGH ) .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics ACP-001 ( TransCon PEG hGH )</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<criteria>Healthy male subject 20 45 year old Body Mass Index 18.5 kg/m2 less equal 29.9 kg/m2 Others Known history hypersensitivity human growth hormone ( hGH ) Known history cardiac , pulmonary , gastrointestinal , endocrine , musculoskeletal , neurological , hematological , immunological , hepatic renal disease , malignancies Others</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>